Chronic prostatitis equals high financial costs, according to research by the Chronic Prostatitis Collaborative Research Network (Arch Intern Med 2004; 164:1231-6).
Surgery is safe for renal cell carcinoma after neoadjuvant immunotherapy
Surgery following neoadjuvant immune checkpoint inhibition with durvalumab plus tremelimumab was shown to be safe in patients with locally advanced renal cell carcinoma.
How APPs can bridge the gap in urologist shortages
In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.
177Lu-PSMA-617 tolerable in patients with mCRPC and baseline cytopenias
"However, these patients have an overall poor prognosis,” noted Mohamed E. Ahmed, MD.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Study compares 18F-based PSMA radiotracers to [68Ga]Ga-PSMA-11
“[18F]DCFPyL was assessed to be a suitable alternative to [68Ga]Ga-PSMA-11 in PCa diagnosis and staging due to its similar lesion uptake rate with no increase in benign uptakes," the authors wrote.
Demystifying Vector-Based Intravesical Gene Therapy for NMIBC: A New Frontier
Neal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.
2 Clarke Drive Cranbury, NJ 08512